Jiangsu Kangyuan Pharmaceutical Co., Ltd. (600557)

Jiangsu Kangyuan Pharmaceutical Co., Ltd. (600557)

Jiangsu Kangyuan Pharmaceutical Co., Ltd. is a large-scale traditional Chinese medicine enterprise focusing on R & D, production and sales of drugs. It is a national key high-tech enterprise, a national technological innovation demonstration enterprise, one of the top 100 enterprises in China's pharmaceutical industry (29th), the fifth among the top 10 Chinese medicine enterprises in China, and the top 20 Chinese medicine enterprises in innovation. It has more than 5000 employees. It has established a number of national scientific research platforms, such as "State Key Laboratory of new technology in traditional Chinese medicine pharmaceutical process". In 2018, the laboratory was awarded "State Key Laboratory of excellent enterprises" (No.1 in the pharmaceutical field). It has obtained 47 national level new Chinese medicine drugs and 331 invention patents; It has undertaken more than 50 scientific and technological projects; One second prize of National Technological Invention Award, two second prizes of national scientific and technological progress award, and eight first prizes of provincial and ministerial scientific and Technological Progress Award (including two first prizes of Jiangsu Scientific and technological progress award); For three consecutive years, R & D strength ranked first in the list of R & D strength of traditional Chinese medicine. Guizhi Fuling Capsule has completed the phase II clinical trial in the United States, and is an international demonstration variety of traditional Chinese medicine in China.

Adhering to the historical mission of "revitalizing Chinese medicine and serving the motherland", the company has formed a development system with the cluster innovation and development of "traditional Chinese medicine, chemical medicine and biopharmaceutical" as the main line and the cultural health industry and health products of traditional Chinese medicine as the two wings. To realize the synchronous development of "quality improvement" and "scale expansion" of the big health industry, and comprehensively enhance the core competitiveness of enterprises.

>> tungsten carbide rings gold